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Abstract
Molecular profiling studies of tumor tissue from patients with clear cell renal cell cancer (ccRCC) have revealed
extensive metabolic reprogramming in this disease. Associations were found between metabolic reprogramming,
histopathologic Fuhrman grade, and overall survival of patients. Large-scale genomics, proteomics, and
metabolomic analyses have been performed to identify the molecular players in this process. Genes involved in
glycolysis, the pentose phosphate pathway, glutamine metabolism, and lipogenesis were found to be upregulated
in renal cell cancer (RCC) specimens as compared to normal tissue. Preclinical research indicates that mutations in
VHL, FBP1, and the PI3K-AKT-mTOR pathway drives aerobic glycolysis through transcriptional activation of the
hypoxia-inducible factors (HIF). Mechanistic studies revealed glutamine as an important source for de novo fatty
acid synthesis through reductive carboxylation. Amplification of MYC drives reductive carboxylation. In this review,
we present a detailed overview of the metabolic changes in RCC in conjunction with potential novel therapeutics.
We discuss preclinical studies that have investigated targeted agents that interfere with various aspects of tumor
cell metabolism and emphasize their impact specifically on glycolysis, lipogenesis, and tumor growth. Furthermore,
we describe a number of phase 1 and 2 clinical trials that have been conducted with these agents.
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Background
Renal cell cancer (RCC) is an aggressive type of cancer
that arises from the proximal renal tubular epithelium of
the kidneys. It occurs as sporadic cancer as well as part
of hereditary cancer syndromes. RCC accounts for ~80 %
of all sporadic kidney cancers and has displayed a rising
incidence over the last decades [1, 2]. Different histo-
logical subvariants of RCC can be recognized with “clear
cell renal cell cancer” representing 88 % in contemporary
pathological series [3]. Papillary and chromophobe cancer
are other subtypes of RCC. Identification of the von
Hippel-Lindau (VHL) gene, as most frequently deleted
gene in RCC cells, accelerated development of vascular
endothelial growth factor (VEGF)-targeted therapy for
treatment of the disease. Silencing of VHL, resulting in ac-
cumulation of the hypoxia-inducible factor (HIF) tran-
scription factors, induces elevated levels of VEGF in
tumor cells. Upregulation of VEGF has been associated
with the rich vascularization of tumors that is typically
seen in tumors of patients with RCC. Five VEGF-targeted
drugs (sunitinib, pazopanib, sorafenib, axitinib, and beva-
cizumab) are registered as therapeutic agent for treatment
of RCC. Despite an increasing number of therapeutic op-
tions, the prognosis of patients with advanced RCC re-
mains dismal. Locally advanced or metastatic RCC cannot
be cured with current treatments.
A large retrospective cohort study was performed by
“The Cancer Genome Atlas” (TCGA) consortium among
patients with RCC [4]. Upregulation of genes involved in
glycolysis was found, while genes, known to play a role
in the tricarboxylic acid (TCA) cycle, were found to be
downregulated [4, 5]. The altered pattern in glucose
metabolism in tumors has first been described by the
German physiologist Otto Warburg as aerobic glycoly-
sis [6]. This phenomenon, nowadays frequently referred
to as “the Warburg effect,” has been found in an im-
portant subset of the patients with RCC and was associ-
ated with a poor prognostic outcome. In this review, we
will provide a detailed overview of the genetic changes
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that cause the Warburg effect, in conjunction with
therapeutic agents that may interfere with this process.
Besides changes in glucose metabolism, numerous
other metabolic changes have been detected in RCC
specimens and include amino acid and lipid metabolism.
Arginine, tryptophan, and glutamine are examples of
amino acids with altered dynamics. Genetic defects in
cancer cells lead to increased import of these amino
acids from the extracellular space. Furthermore, upregu-
lation was found of genes involved in de novo fatty acid
synthesis (lipogenesis) by TCGA [4]. Upregulation of
lipogenesis and intracellular storage of lipid droplets
causes the typical histopathological “clear cell” pheno-
type in RCC (clear cell renal cell cancer (ccRCC)) [7].
Preclinical research indicated that increased lipid stor-
age also alleviates endoplasmic reticulum (ER) stress
[7]. Dependence on extracellular amino acid supplies
and upregulation of lipogenesis were shown to create
vulnerabilities that can potentially be exploited by
therapeutic agents such as Peg-Arg-1 and 5-(tetradecy-
cloxy)-2-furoic acid (TOFA) [8, 9].
Tumors with nutrient metabolism reprogramming
carry a poor prognostic outcome, which suggests poten-
tial of this process as a drug target. The metabolic
changes are a common molecular feature of advanced
RCC tumors. The frequency of genetic changes is of im-
portance for the selection of potential therapeutic tar-
gets. The fundamental idea of anticancer drugs is to
target molecules and cellular processes that are essen-
tial for tumor cell survival and less important to non-
proliferating normal cells. Selective pressure due to
survival advantage of certain genetic defects may give
enrichment of those alterations in tumors. A higher
frequency of these genetic defects in patient series also
creates a larger platform for drugs that specifically
interfere with it. The VHL-HIF-VEGF axis as most fre-
quently activated pathway in RCC and therapeutic tar-
get is here an exemplary case. The frequency of the
metabolic reprogramming may render RCC a suitable
disease for the investigation of potential novel thera-
peutic agents that target tumor metabolism.
Part I. Metabolic pathways with altered activity in
human RCC
Results from molecular profiling studies of human RCC
specimens
Frequent mutation of components in the PI3K-AKT-
mTOR signaling pathway was found in early genetic se-
quencing studies [10]. TCGA consortium performed an
integrated genome, transriptome, proteome, and methy-
lome analysis of tumor specimens from 400 patients
with ccRCC [4]. Mutation of PTEN, TSC1/2, and PIK3CA,
which were detected in the early sequencing studies and
all reside in the PI3K-AKT-mTOR pathway, could be
confirmed by TCGA in 28 % of the tissues. Further-
more, they were the first to report comprehensive in-
formation on the RNA expression levels of various
genes involved in metabolism (see Fig. 1 for an over-
view of the alterations). Fatty acid synthesis (FASN)
and the glutamine- (SLC1A5) and lactate transporter
genes (MCT1 and MCT4) were frequently found to be
upregulated in aggressive tumors. Hexokinase, phos-
phofructokinase (PFK), pyruvate dehydrogenase kinase
(PDK), alpha-enolase (ENO1), and lactate dehydrogen-
ase (LDH-A) are critical enzymes in the glycolytic reac-
tions and also examples of upregulated genes in TCGA
RNA expression analysis [4]. Overexpression of LDH-
A, MCT4, and ENO1 has been confirmed in independ-
ent patient cohorts [11–14]. The pentose phosphate
pathway (PPP) branches from the glycolytic pathway
and also appeared to be activated. Glucose-6-phosphate
dehydrogenase (G6PD) and transketolase (TKT) are bi-
directional and rate-limiting enzymes in the PPP with
elevated expression levels [4]. Aconitase 2 (ACO2), α-
ketoglutarate dehydrogenase (OGDH), and succinate
dehydrogenase (SDHB) are examples of enzymes in the
TCA cycle with diminished expression in TCGA RNA
expression analysis [4]. Reduced AMP-activated kinase
(AMPK) and increased acetyl-CoA carboxylase (ACC)
protein levels were observed with a notable independent
association with poor overall survival of patients [4].
Gene expression profiles have also been analyzed
through mass spectrometry [15]. This analysis revealed
upregulation of protein levels of glyceraldehyde-
phosphate-dehydrogenase (GAPDH), phosphoglycerate
kinase (PGK1), ENO2, pyruvate kinase (PKM2), and
LDH-A in RCC specimens (n = 40) as compared to nor-
mal tissue [15]. The TCA cycle enzymes pyruvate carb-
oxylase (PC), SDHA, and SDHB were downregulated.
The same pattern was observed for enzymes involved
the β-oxidation of fatty acids like hydroxylacyl-CoA de-
hydrogenase (HADH), short-chain enoyl-coA hydratase
(SCEH), very long chain acyl-coenzyme A dehydrogen-
ase (VLCAD), acetyl-coA acetyltransferase (ACAT1),
and medium-chain acyl-coA dehydrogenase (MCAD).
No significant differences in isocitrate dehydrogenase
(IDH1/2) protein levels were observed between RCC
and normal kidney tissues.
Regulation of glycolysis, amino acid metabolism, and
lipogenesis has also been subject of two metabolomics
studies performed on a single cohort of 138 patients
with RCC [16, 17]. Real-time flux analysis provides su-
perior information on upregulation of metabolic path-
ways as compared to the snapshot analysis performed
in these two studies. Both up- and downregulation of
individual metabolites can be indicative of increased
metabolism, which hampers the interpretation of the
results. Both Wettersten et al. and Hakimi et al. showed
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increased glucose, glu-6-P, fru-6-P, and lactate levels in
RCC tissue as compared to healthy control tissue with
notable association with the histopathologic nuclear
grading system according to Fuhrman. Lower levels of
TCA intermediates malate and fumarate were detected,
while citrate and succinate were elevated. The levels of
free fatty acids, glutamine, glutathione (GSH), and
glutathione disulfide (GSSG) were increased and dis-
played an association with Fuhrman grade [16, 17]. Ele-
vations of numerous consecutive metabolites (glucose,
glu-6-p, fru-6-p, 6-PG) and their corresponding en-
zymes (HK, G6PD) do suggest upregulation of the first
steps of the glycolytic pathway.
Certain aspects of these metabolomics studies require
further investigation. Integrated analyses of transcripto-
mics and metabolomics showed a lack of linearity. For
example, a remarkable depletion of a number of glyco-
lytic metabolites (3-PG, 2-PG, and PEP) was noted along
with overexpression of their corresponding glycolytic en-
zymes (PGK1, ENO2, PKM; see also Fig. 1) [17]. These
results may reflect the fact that metabolic flux patterns
do not always follow canonical flow but link and shunt
into neighboring pathways. They indicate that more dy-
namic flux analyses are required to improve our under-
standing of this aspect of cancer biology. Moreover, they
stress the importance of functional interference studies
for development of therapeutics. The association be-
tween metabolites and Fuhrman grade does indicate that
the natural disease course in patients with RCC, as
reflected by increasing Fuhrman grade, is accompanied
by progressive metabolic reprogramming.
The most recent metabolomics study marked shunt-
ing of glucose in the PPP and production of glutathi-
one as poor prognostic features [17]. This conclusion
is in agreement with the conclusion of the analysis by
TCGA. Elevated levels of glucose corresponded to in-
creases in the PPP intermediate 6-phosphogluconate
(6-PG), supporting elevated PPP-flux. In addition,
higher levels of GSH were detected along with its pre-
cursor glutamine in the poor prognosis subgroup. GSH
buffers reactive oxygen species by serving as electron
donor, which is accompanied by oxidation to GSSG.
GSSG can be converted back to GSH by glutathione
reductase. This reaction requires NADPH, which is an
important product of G6PD activity in the PPP.
Through this role, the PPP is thought to contribute to
an improved redox state of RCC cells. High levels of
GSH coincided with hotspot mutations in the gene en-
coding NRF2 and its negative regulator KEAP1. NRF2
is known to drive expression of multiple components
of antioxidant defense system, including the GSH-
producing enzymes [18]. Late stage RCC tumors may
therefore increase the capacity to buffer oxidative
stress, not only through upregulation of the PPP but
also through activation of the NRF2 antioxidant re-
sponse pathway.
Fig. 1 An overview of the molecular players in the metabolism of glucose, fatty acids, and glutamine. Pathways were divided in five different sections
based on recognition as different entity in biochemical literature. Molecules labeled green were found to be upregulated in RCC specimens, while red
molecules were downregulated
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Molecular drivers of the metabolic reprogramming in RCC
Genome-wide association studies suggest a role of
chromosome 3p loss in the metabolic reprogramming in
RCC. The VHL, along with the metabolic regulator
pyruvate dehydrogenase B (PDH-B), resides on a 50-Mb
stretch of DNA on this chromosome. A large chromo-
somal copy number analysis indicated that this region is
the most frequently deleted region in RCC (91 % of the
samples) [19]. Loss of chromosome 3p and VHL corre-
lated with divergence of metabolic gene expression in a
large meta-analysis [5]. PBRM1, SETD2, and BAP1 are
chromatin-modifying genes also located at chromosome
3p, but until now, no role has been identified for these
genes in regulation of metabolism.
Transcriptional activity of the HIF may be the driving
force behind the Warburg effect in RCC. Two isoforms
of HIF exist, with the majority of RCC tumors (61 %) ex-
pressing both isoforms [20]. Loss of VHL results in nor-
moxic HIF stabilization and enhances transcription of
target genes. HIF1 was found to drive expression of
GLUT1, PGK1, LDH-A, PDK1, and HK2 in transgenic
mice with differential HIF1/HIF2 expression [21]. Sup-
pression of oxidative phosphorylation in the TCA cycle
was also found to be mediated by HIF1, through its tar-
get gene Dec1 and the transcriptional coactivator PGC-
1α [22]. While evidence supports an important role of
HIF1 in promoting aerobic glycolysis [21], it has also
been shown to act as a tumor suppressor in preclinical
RCC models [23]. Indeed, some tumors appear to have
lost the HIF1 locus on chromosome 14q23, but surpris-
ingly, no correlation was found between this deletion
and HIF1A protein expression in RCC samples [19]. Fu-
ture research will have to show whether correlations
exist between HIF1 and/or HIF2 and the metabolic
phenotype of RCC tumors.
Although loss of VHL may be a crucial event in RCC
tumorigenesis, isolated loss does not elicit the characteris-
tic HIF-transcriptional signatures [24]. Loss of fructose-
1,6-bisphosphatase 1 (FBP1) on chromosome 9q22 is an-
other unique feature of RCC [19]. Examination of its
expression in 600 human RCC specimens revealed de-
pletion in almost 100 % of the tumors as compared to
normal kidney tissue [25]. Manipulation of FBP1 in
normal kidney cells recapitulated numerous features of
ccRCC tumors with markedly elevated glucose con-
sumption and increased production of lactate, GSH,
and NADPH [25]. Under physiological conditions,
FBP1 opposes glycolysis and supports gluconeogenesis
through production of Fru-6-p from Fru-1,6-P2 (see
Fig. 1). In addition to this role in gluconeogenesis, the
molecule was found to interact directly with HIF1 and
HIF2, restraining their transcriptional activity [25]. Loss
of FBP1 was associated with expression of several HIF-
target genes, including PDK1, LDH-A, and GLUT1
[25]. Combined loss of VHL and FBP1 may therefore
be an essential step in the development of the aerobic
glycolysis phenotype in RCC.
The previously described molecular profiling studies
revealed high levels of glutamine and free fatty acids in
RCC specimens. Preclinical research indicates that these
upregulated levels may be related to each other. In
addition to its function as GSH precursor, glutamine can
be transformed into α-ketoglutarate and oxidized in the
TCA cycle. OGDH, which is the enzyme responsible for
metabolism of α-ketoglutarate in the TCA cycle, was fre-
quently found to be downregulated in RCC cells. IDH
diverts α-ketoglutarate in the opposite direction in the
TCA cycle through a process called “reductive carboxyl-
ation” [26]. Glutamine is transformed into citrate and
acetyl-CoA in this pathway (Fig. 1) [27]. ACC and FASN
mediate subsequent formation of fatty acids. The ele-
vated levels of the ACC and FASN gene products as well
as glutamine, citrate, and fatty acids in RCC specimens
support potential activation of this pathway. High levels
of fatty acids were measured in RCC cells, along with
downregulation of the enzymes involved in β-oxidation
[15]. Histological analysis showed intracellular storage of
fatty acids as “lipid droplets” near the ER [7]. Storage of
lipids relied on the HIF2-dependent gene perilipin 2
(PLIN2) and suppressed cytotoxic ER stress through a
reduction of protein synthesis [7]. This information
shows that tumor cells may upregulate glutamine-
dependent lipogenesis to reduce ER stress.
Dual activation of HIF2 and MYC seems to induce
glutamine-dependent lipogenesis. Focal amplification was
found of chromosome 8q24 in RCC specimens, which is
the locus of the transcription factor MYC [4]. Overexpres-
sion of MYC in transgenic mouse models of RCC induced
upregulation of glutaminases (GLS1-2) and transporters
(SLC1A5) and elevated levels of glutamate and α-
ketoglutarate [28]. Upregulation of glutamine metabolism
was also accompanied by accumulation of lipids in RCC
tumors [28]. In addition to MYC, a role has been iden-
tified for HIF2 in glutamine-dependent lipogenesis [29].
Expression of a constitutively active HIF2 molecule
followed by metabolic flux analysis, revealed a shift of
IDH/ACO towards reductive carboxylation of glutam-
ine to citrate [29]. Experiments with labeled glutamine
isotopes showed increased production of lipogenic
acetyl-coA upon expression of this active HIF2 mol-
ecule [29]. Furthermore, HIF2 is known to enhance
transcriptional activity of MYC directly through in-
creased promotor binding [30]. Altogether, this infor-
mation implicates a concerted effort of HIF2 and MYC
in activation of glutamine-dependent lipogenesis.
The activation of mTOR may also contribute to the
metabolic phenotype of RCC tumors. Isolated activation
of mTORC1 through TSC1/2 knock out induced a gene
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expression profile consistent with aerobic glycolysis [31].
Subsequent analysis of target genes combined with func-
tional interference experiments revealed that HIF1 is re-
sponsible for the glycolytic response in this model [31].
Upregulation of HIF1 and HIF2 protein levels were
thought to be induced by mTORC1-mediated inhibition
of 4E-BP1 [31]. SREBP1/2 were other critical players that
were found to act downstream of mTORC1. The latter
transcription factors were found to drive the gene ex-
pression of G6PD and FASN [31] (Figs. 1 and 2).
Studies focusing on down- and upstream signaling part-
ners of mTORC1 also claimed a role in regulation of me-
tabolism. AKT is an example of an upstream signaling
partner of mTORC1, which indirectly promotes its activity
through inhibition of TSC2 [32]. Activity of AKTcorrelated
with expression of glucose transporters (GLUT1), hexoki-
nase (HK), and PFK1 in cancer cells (Fig. 2) [33–35]. Iso-
lated overexpression of activated AKT stimulated aerobic
glycolysis and rendered cells susceptible to glucose with-
drawal [36]. AMPK on the other hand is a player that nega-
tively affects mTORC1 signaling. It reduces mTORC1
activity through TSC2. Enhanced AMPK activity rescued
cancer cells from AKT-dependent glucose addiction
through activation of beta-oxidation of fatty acids [37].
These results suggest that the TSC2-mTORC1 axis is of
importance for the impact of AKT on tumor metabolism.
Decreased protein expression of AMPK and activating mu-
tations in the PI3K-AKT-MTOR pathway are frequently
observed in RCC tumors [4]. These results provide at least
circumstantial evidence that mTORC1, although partly
through HIF-mediated mechanisms, contributes to the
metabolic phenotype of RCC tumors.
Part II. Targeting metabolic reprogramming in
preclinical models
GLUT-1 and hexokinase inhibitors
Uptake of glucose is primarily mediated by the GLUT-1
transporter, which can be targeted by drugs. Selective
blocking of this transporter by the drug STF-31 was
found to impede glucose uptake and selectively inhibit
growth of RCC tumors [38]. Fasentin and WZB117 are
other GLUT1-inhibitors with comparable effects on intra-
cellular glucose levels. WZB117 induced activation of the
ATP-sensing enzyme AMPK in lung cancer xenografts,
indicating that it induces metabolic stress [39]. A direct
comparison of these drugs has not been performed.
Hexokinase commits glucose to the glycolytic pathway
and has been target of treatment for several decades.
Particularly, the chemically modified glucose analog 2-
deoxy-D-glucose (2DG) is a drug with a long-standing
history in cancer research. The additional hydroxyl-
group in 2DG prohibits metabolism after phosphoryl-
ation by hexokinase. The chemical modification thereby
induces accumulation of 2-deoxy-glucose-6-phosphate,
which inhibits hexokinase activity. No recent results
have been published on application of the drug in pre-
clinical RCC models. The drug 3-bromopyruvate (3-
BrPa) is a second drug that interferes with hexokinase
activity. Four isoforms of hexokinase have been identi-
fied to date. Hexokinase 2 was found to associate with
anion channels at mitochondria, which appears import-
ant for mitochondrial homeostasis [40]. While 2DG acts
as substrate for hexokinase, 3-BrPa is believed to inter-
fere directly with its enzymatic activity and covalently
bind hexokinase 2, which disrupts its association with
mitochondria [40]. MCT1 facilitates import of 3-BrPA
and its expression is therefore of crucial importance for
sensitivity to the drug [41]. Treatment with 3-BrPa
markedly reduced ATP production and induced cell
death in primary RCC cell lines [42]. Lonidamine (LND)
is the third drug that interferes with hexokinase activity.
Application depleted intracellular ATP levels through
inhibition of hexokinase 2 (HK2) and induced accu-
mulation of lactate in cells [43]. A comparison be-
tween 3-BrPA and LND in glioblastoma cell lines
revealed a different mechanism of cell death [44]. Ac-
cumulation of lactate and the different cell death
mechanism suggest additional effects of LND on cel-
lular metabolism in addition to HK2 inhibition. LND
has not been tested in preclinical RCC models.
Inhibitors of the pentose phosphate pathway
G6PD and TKT are critical enzymes in the pentose
phosphate pathway, whose activity can be blocked by
drugs. Activity of hexokinase delivers glucose-6-phosphate
which can be directed into the PPP (Fig. 3). The pathway
consists of two distinct phases. G6PD is the rate-limiting
enzyme in the oxidative phase, which generates NADPH
and ribul-5-p. TKT acts as a critical enzyme in the second
non-oxidative phase, which serves to recycle ribul-5-p
back to the glycolysis through generation of Fru-6-p
(Fig. 3). Silencing of TKT in hepatocellular carcinoma
Fig. 2 Connections between the PI3K- and metabolic pathways are
shown. Given their central role in the pathogenesis of RCC, p110alpha,
Akt, and mTORC1 are labeled orange
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cells induced accumulation of ribul-5-p and rib-5-p [45].
Importantly, TKT and TALDO were found to function as
bidirectional enzymes, having the ability to promote the
reverse reaction. Depending on the metabolite balance in
cancer cells, inhibition of TKT therefore may not neces-
sarily reduce the production of Fru-6-p.
6-Aminonicotinamide (6-AN) and dehydroepiandros-
teron (DHEA) are G6PD inhibitors that have been tested
as experimental treatment. The drug 6-AN elevated oxi-
dative stress in RCC cell lines through a decrease in
NADPH [46], which is a known product of the PPP.
Novel small molecule inhibitors with favorable pharma-
cokinetic properties are in development [47]. HDM2 an-
tagonists are another class of drugs that may reduce
G6PD activity. They induce accumulation of p53, which
directly interacts with G6PD and blocks its function
[48]. HDM2 antagonists such as MI319 have been tested
in combination with sunitinib in RCC xenograft models
and showed potent reduction of tumor growth [49].
Beneficial effects of HDM2 inhibitors could, however,
also be mediated by other p53-dependent effects.
TKT is the second critical enzyme in the pentose
phosphate pathway. Oxythiamine and hydroxyphenyl-
pyruvate are examples of TKT inhibitors. Oxythiamine
was found to be an effective treatment in hepatocellu-
lar carcinoma xenografts. Here, it reduced tumor
growth through elevation of oxidative stress [45].
Treatment of Ehrlich’s ascitic tumor cells with
oxythiamine significantly reduced the synthesis of ri-
bose, which is a main product of the PPP and an im-
portant source for nucleic acid catabolism [50]. A
variant of this thiamine analog has been generated
with improved TKT specificity, but requires further in-
vestigation in preclinical models [51].
Inhibitors of glycolytic enzymes
PFK1 catalyzes the production of fructose-1,6-bispho-
sphate (Fru-1,6-P2) from fru-6-p. The bidirectional enzyme
PFK2-FBase regulates the production of fructose-2,6-
bisphosphate (Fru-2,6-P2) from fru-6-p. Fru-2,6-P2 stimu-
lates glycolysis through allosteric activation of PFK1 (Fig. 3).
Four different isoforms of PFK2-FBase are known to be
expressed in human tissues. The PFK-FB3 isoform was
found to be preferentially expressed in cancer cells. The
drug PFK15, as well as its predecessor 3PO, interferes with
the enzymatic function of the kinase. As a consequence of
treatment, reduced intracellular Fru-2,6-P2, lactate and
ATP levels were detected in leukemic-, lung-, and breast
cancer cells, which confirms on-target effects [52]. Treat-
ment also induced potent antitumor effects in multiple
xenograft models of cancer [53].
Fructose-bisphosphate-aldolase, GAPDH, PGK, phos-
phoglycerate mutase (PGAM1), and ENO1 are other
enzymes involved in glycolytic reactions (Fig. 3). Small
molecule inhibitors of GAPDH (FK866), PGAM1
(PGMI-004A), and ENO (ENOblock) have been
Fig. 3 An overview of identified glycolytic inhibitors is shown along with their corresponding targets
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discovered [54–56]. Pharmacological blockade of PGAM1
reduced glycolysis and resulted in accumulation of 3-
phosphoglycerate (3-PG). Unexpectedly, PGAM1 inhibitors
activated a feedback loop that reduced 6-phosphogluconate
dehydrogenase (6-PGDH) activity and flux through the
PPP [56]. A shift in the melting temperature of 6-PGDH
was found in the thermal melt assay upon incubation with
increasing concentrations of 3-PG. Further crystal structure
analysis confirmed direct binding of 3-PG to 6-PGDH at
sites important for enzymatic activity. Blockade of the PPP
at the level of 6-PGDH through a toxic buildup of 3-PG
therefore seems a mechanism for this activity [56].
PK catalyzes the final reaction in glycolysis and thera-
peutic strategies have been developed that target PK. In
normal cells, PK generates ATP and pyruvate through
dephosphorylation of phosphoenolpyruvic acid (PEP).
The M2 isoform (PKM2) was shown to be preferentially
expressed in cancer cells and promote aerobic glycolysis
[57]. Interestingly, it was not its enzymatic activity but
rather its ability to bind phospho-tyrosine proteins
that was shown to promote aerobic glycolysis (Fig. 2)
[58, 59]. Expression of PKM2 protein was found to be
increased in human RCC specimens [15]. A systematic
search for small molecules that selectively target
PKM2 yielded numerous compounds that mimicked
gene silencing in lung cancer cells [60]. Activation of
enzymatic activity was also shown to serve as potential
therapeutic strategy. PKM2 activity is known to be
stimulated by upstream Fru-1,6-P2 through binding to
a unique domain, which induces a conformational
change. Compounds have been developed that mimick
Fru-1,6-P2 activity in lung cancer cells and lock PKM2
in its active state [61]. Activation of PKM2 was shown
to create a unique dependence of cancer cells on
extracellular serine, most likely through reduced avail-
ability of 3-PG [61]. Tests of PK-M2 targeting strat-
egies in xenografts and preclinical RCC models are
lacking, and therefore, their role in this disease still
has to be determined.
Inhibitors of pyruvate and lactate metabolism
PDH converts pyruvate into acetyl-coA, while LDH
transforms it into lactate. PDK inactivates PDH through
its phosphorylation. Therapeutic strategies that interfere
with pyruvate metabolism have focused on PDK in order
to promote use of the TCA cycle. Downregulation of
PDK both increased respiration and oxidative stress
through activation of the TCA cycle [62]. Dichloroacetic
acid (DCA) is an example of a PDK inhibitor that acts as
pyruvate mimetic. DCA was found to reverse mitochon-
drial suppression and reduce tumor size of preclinical
RCC xenografts [63]. AZD7545 and VER-246608 are
other drugs that inactivate PDK through binding at dif-
ferent structural sites [64]. VER-246608 is an ATP-
competitive PDK inhibitor, which enhanced PDH activity
and cellular respiration and attenuated glycolytic activity
in cancer cell lines [65].
LDH catalyzes the final step of aerobic glycolysis and
represents another attractive target for treatment (Fig. 3).
Similar to PDK inhibitors, downregulation of LDH-A
was found to promote respiration in FH-deficient RCC
cells [66]. At least two small molecule inhibitors have
been tested in preclinical models. AT-101 or gossypol
is an unspecific inhibitor of multiple dehydrogenase
enzymes, including LDH-A. Its derivative FX11 is an
example of a LDH-inhibiting compound, that was suc-
cessfully tested in RCC models [67]. Treatment increased
oxygen consumption and oxidative stress, indicating that
pyruvate is shunted into the TCA cycle. Oxamate repre-
sents a second example of a promising LDH-inhibitor.
Treatment induced similar metabolic results as found with
FX11 with additional activation of autophagy in NSCLC
cells [68]. N-hydroxyindole-2-carboxylates (NHI) are cur-
rently under investigation as next-generation LDH inhibi-
tor. Epigallocatechin gallate (EGCG) may also have
activity as LDH inhibitor but was found to interfere with
other metabolic enzymes. Its utility as LDH inhibitor re-
mains to be shown.
Under physiological circumstances, lactate, as well as
glycerol, can be employed for gluconeogenesis. The
mitochondrial enzyme glycerophosphate dehydrogenase
(GPDH) converts glycerol-3-phosphate (glyc-3-p) into
dihydroxyacetone phosphate (DHAP) (Fig. 4). This reac-
tion yields significant amounts of NAD+, which is re-
quired for the production of glucose from lactate. The
antidiabetic drug metformin was found to block gluco-
neogenesis through specific targeting of the mitochon-
drial isoform of GPDH [69]. Secondary to these effects,
AMPK activation was found in cancer cells treated with
metformin, restraining mTORC1 signaling and limiting
growth of renal cell cancer xenografts [70]. The import-
ance of a functional AMPK-TSC1-mTORC1 pathway
for metformin has been illustrated by the lack of re-
sponse in a TSC1(+/−) transgenic model [71]. Frequent
downregulation of AMPK has been observed in RCC
and therefore makes the potential of the drug in RCC
questionable.
Inhibition of lactate transport has been investigated as
therapeutic strategy. The monocarboxylate transporters
1 and 4 (MCT1/4) facilitate lactate export from cancer
cells and prevent a toxic buildup of the metabolite
(Fig. 3). Downregulation of the MCT4 (SLC16A3) trans-
porter was identified as therapeutic strategy through
whole genome siRNA screens in RCC cell lines [72].
Lactate export is accompanied by H (+) transport
across the plasma membrane. Through interference
with intracellular pH, rapid cytotoxic effects are in-
duced. AZD3965, a-cyano-4-hydroxy-cinnamate (CHC),
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and AR-C155858 are examples of drugs that interfere
with lactate export through blockade of MCT1.
AZD3965 treatment effectively induced lactate accumu-
lation in small cell lung cancer xenografts [73]. AR-
C155858 and CHC curtailed lactate secretion along
with lower pH levels and cytotoxic effects in multiple
myeloma cells [74]. Effectivity of MCT1 inhibitors ap-
pears to rely on low MCT4 expression levels [75],
which suggest some functional redundancy. Both trans-
porters seem to be expressed in RCC [13, 72]. Interest-
ingly, silencing of MCT4 expression alone did affect the
viability of RCC cells [72]. Future research will there-
fore have to focus on development of MCT4 or poten-
tial dual MCT1/4 inhibitors for patients with RCC.
Arginine- and other amino acid-depleting treatment
strategies
Metabolomics studies revealed decreased levels of almost
all amino acids (except cysteine, glutamate, and glutam-
ine) in RCC tumors as compared to normal kidney tissues
[17]. In contrast, upregulation of genes involved in nucleo-
tide and particularly pyrimidine synthesis was found in a
meta-analysis of TCGA data [5]. Glutamine acts as source
for nucleotide biosynthesis through conversion into TCA
cycle intermediates [76]. ASS1 is an example of a gene in-
volved in both amino acid and nucleotide metabolism.
Downregulation of ASS1 has been detected in an inde-
pendent analysis of RCC specimens [8]. ASS1 and down-
stream argininosuccinate lyase catalyze the conversion of
aspartate into arginine. Lack of ASS1 results in accumula-
tion of aspartate in the cytosol, which is subsequently di-
rected into the pyrimidine and nucleotide synthesis
pathway [77]. Downregulation of ASS1 therefore pro-
motes generation of nucleotide precursors and also makes
RCC cells dependent on extracellular arginine.
Depletion of extracellular arginine, through adminis-
tration of pegylated arginase 1 (Peg-Arg-1) or arginine
deiminase (ADI), has been explored as an anticancer
treatment. It has been tested in RCC xenograft models
as therapeutic strategy [8]. Dose-dependent inhibition of
tumor growth was observed. Reconstitution of ASS1 in-
duced resistance to ADI in vitro. Similar treatment ef-
fects were seen in hepatocellular carcinoma (HCC) and
melanoma xenografts, with a sustained decrease in intra-
tumoral arginine levels [78]. Unfortunately, many im-
mune cells rely on extracellular arginine [79]. Arginine
depletion therapy therefore has immunosuppressive ef-
fects, which possibly limits its efficacy in mice.
Tumor cells meet their essential amino acid demands
by upregulation of specific transporters. The L-type
amino acid transporter 1 (LAT1) is an example of an up-
regulated transporter in ccRCC [80]. It transports large
neutral branched amino acids, such as the leucine and
tryptophan. LAT1 recognizes amine and carboxylic acid
side groups in substrates, which determines its select-
ivity. Drugs (JPH203, 3,5-diiodo-L-tyrosine, acivicin)
have been developed that exploit this feature and
competitively inhibit LAT1 activity. Treatment with
JPH203 induced dramatic inhibition of leucine uptake
and proliferation of colorectal cancer cells [81].
In line with the elevated expression of LAT1, increased
tryptophan metabolism has been detected in RCC speci-
mens [16]. Particularly, upregulation of the metabolic
enzyme indoleamine 2,3-dioxygenase (IDO1) has been
observed as a frequent feature [82]. This enzyme stimu-
lates conversion of tryptophan into the immunosuppres-
sive metabolite kynurenine [83], which was also found
to be elevated in RCC [16]. The IDO-inhibitors L-1-
MT, 1-D-MT, INCB024360, and indoximod have been
developed and give various degrees of IDO-blockade. A
decrease in kynurenine production was found in vitro
[16, 84]. Effectivity of these inhibitors has not been
tested in RCC xenograft models.
Inhibitors of glutamine metabolism
Glutamine analogs as well as inhibitors of physiological
glutamine import have been used as therapeutic agents
in preclinical studies. In addition to its function as an
energy and lipid source, glutamine participates in many
enzymatic reactions. The glutamine analogs 6-diazo-5-
oxo-L-norleucine (L-DON, NSC 7365), acivicin (NSC
163501), and azaserine (NSC 742) block the function of
glutamine utilizing enzymes (Fig. 4). Pharmacological in
vitro studies using leukemia cells identified inhibition of
amidotransferases and nucleotide biosynthesis as princi-
pal mechanism of action [85]. Import of glutamine into
Fig. 4 A schematic overview of drugs that may interfere with
glutamine-dependent lipogenesis
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cancer cells is exerted by SLC1A5 (ASCT2). Gamma-L-
glutamyl-p-nitroanilide (GPNA) and benzylserine (H-
Ser(Bzl)-OH) are targeted inhibitors of this transporter
that reduce growth of lung cancer xenografts. GPNA
treatment of lung and prostate cancer cells diminished
glutamine consumption and generation of fatty acids
and induced autophagy, suggesting that it causes meta-
bolic stress [86, 87]. None of these inhibitors has been
tested in preclinical RCC models.
Glutaminase (GLS) is the enzyme involved in the
conversion of glutamine into glutamate (Fig. 4). It
can be targeted with the chemical inhibitors bis-2-
(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide
(BPTES), bromo-benzophenanthridinone 968 and CB-
839. The inhibitor BPTES has been successfully tested in
preclinical RCC models. It suppressed growth of RCC xe-
nografts in two independent studies [28, 29]. Application
of BPTES in glioblastoma cell lines reduced glutaminase
activity with reduced glutamate and α-ketoglutarate pro-
duction [88]. Similar results have been obtained with CB-
839 in breast cancer cells [89].
Glutamate dehydrogenase (GDH) converts glutamate
into α-ketoglutarate (Fig. 4). Hexachlorophene, GW5074
and bithionol are GDH-inhibitors. Their structure was
based on the green tea polyphenol epigallocatechin gall-
ate (EGCG). This drug has frequently been used in pre-
clinical experiments as GDH-inhibitor [90, 91], although
it may have a variety of other effects in cancer cells.
Amino oxyacetate (AOA) is a well-characterized inhibi-
tor of transaminases [92]. AOA was shown to affect
glutamate metabolism via a pathway involving an ami-
notransferase, presumably aspartate aminotransferase
[93]. Both AOA and EGCG effects were shown to be
rescued by supplementation of molecules such as α-
ketoglutarate or oxaloacetate, supporting specific ef-
fects on glutamine metabolism [91, 94].
Oxalomalate and 2-methylisocitrate are NADPH-
competitive IDH inhibitors. Reductive carboxylation of
α-ketoglutarate by IDH was shown to be the dominant
pathway for generation of citrate and lipids in RCC cells
[27, 95]. Both oxalomalate and 2-methylisocitrate reduced
integration of isotope-labeled glutamine into citrate and
lipids in adipocytes [96]. Discovery of IDH1 mutations in
certain diseases urged development of mutant specific in-
hibitors such as AGI-5198 IDH C-35, AG120, and AG221.
Limited affinity for wild-type IDH1/2, such as observed in
RCC, was found, leaving little room for application in this
disease [97]. In addition to citrate, 2-hydroxyglutarate (2-
HG) is produced during reductive carboxylation of α-
ketoglutarate [95]. Accumulation of 2-HG was found in
RCC cells, which was mainly attributed to decreased ex-
pression of the degrading enzyme 2-HG dehydrogenase
(L2HGDH) [98]. No therapeutic strategies have been devel-
oped to target this last enzymatic process.
Inhibitors of lipogenesis
Citrate can be transported out of the mitochondria and
cleaved to acetyl-coA by ATP citrate lyase (ACLY). Ac-
tivity of ACLY can be blocked by the chemical inhibitors
SB-204990 and SB-201076. The depletion of ACLY in-
hibits proliferation of lung-, liver-, and prostate cancer
cells under lipid-deprived growth conditions, supporting
a crucial role in lipogenesis [99]. Significant reductions
in acetyl-coA levels were found in cancer cells after
treatment with the chemical ACLY inhibitor SB-204990
[100]. Single agent activity was shown in lung and pros-
tate cancer xenograft models with predominantly cyto-
static effects [100]. No results have been published with
these agents in RCC models.
ACC carboxylates acetyl-coA to form malonyl-coA. Its
expression was independently associated with worse
clinical outcome of patients with RCC. Three chemical
inhibitors of ACC have been tested as anticancer treat-
ment. Downregulation of ACC through RNA interference
or with the chemical inhibitor soraphen A attenuated fatty
acid synthesis and proliferation of prostate cancer cells
[101]. The cytotoxic effects were abolished by supplemen-
tation of culture media with fatty acids, which supports
interference with lipid metabolism as the principal mech-
anism of action. CP-640186 and TOFA are the other two
chemical inhibitors that have been tested in preclinical
liver and breast cancer models [9, 102]. Treatment of
breast cancer cells with TOFA reduced malonyl-coA levels
[103], confirming on-target effects of this drug.
FASN converts malonyl-coA to long-chain fatty acids.
Inhibition of FASN by cerulin or its derivative C75 in-
duced a rapid increase in malonyl-coA with a marked
reduction in lipogenesis in multiple cancer models, in-
cluding RCC cells [103, 104]. In addition to effects on
lipogenesis, accumulation of malonyl-coA may have
cytotoxic effects in itself. Orlistat, GSK 837149A,
G28UCM, and triclosan are other FASN inhibitors that
have shown to limit proliferation of prostate and ovar-
ian cancer cells [105–107]. Consistent with inhibition
of de novo fatty acid synthesis, G28UCM and C75
treatment caused conversion of membrane lipids into
storage lipids in ovarian cancer cells [107]. A reduction
in overall lipid content was found after triclosan and
C75 treatment in prostate cancer cells [105].
Inhibitors of the PI3K-AKT-mTOR pathway
Due to the abundance of molecular alterations in the
PI3K-AKT-mTOR pathway in RCC, several therapeutic
strategies have been explored. Many of the inhibitors de-
scribed below exhibit cross-activity against other compo-
nents of the pathway (for example, dual PI3K/mTOR
inhibitors). More information about the pharmacological
aspects of these drugs can be found elsewhere. Activat-
ing mutations in p110 and p85 subunits of PI3K as well
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as inactivating mutations in the PTEN phosphatase pre-
sumably render tumors susceptible to targeted inhibi-
tors. Indeed, promising results have been achieved with
PI3K-inhibitors such as NVP-BEZ235, GDC-0980, and
LY294002 in renal cell cancer models [108–112]. Perifo-
sine (KRX-0401) is an example of an AKT inhibitor that
has been described to reduce proliferation of RCC cells
[113]. Clinical activity of rapalogs (temsirolimus, everoli-
mus) in patients with RCC elicited development of next-
generation mTOR inhibitors. Particularly enhanced ac-
tivity against mTORC2 seems to improve efficacy and
these agents are therefore awaiting clinical tests. WYE-
125132, WYE-354, P7170, and AZD8055 are examples
of novel mTOR inhibitors that induced tumor shrinkage
in preclinical RCC models [114–117].
Part III. Clinical trials on metabolic inhibitors
Clinical experience with metabolic inhibitors
Many of the drugs that were tested in early stages of
drug development in oncology were targeting metabolic
components of tumors. New insights from molecular
profiling of numerous diseases and preclinical experi-
ments may urge a revival of drugs from this era. Al-
though these drugs have been tested in the clinic, it
remains uncertain whether dosing, treatment schedule,
tumor type, and response evaluation in these trials were
adequate. In the ideal situation, one prefers to evaluate
on-target effects in patient-derived tumor tissue. This
last action may differentiate between suboptimal dosing
regimens, pharmacologically inferior drugs, and unviable
drug targets. From common genetic polymorphisms that
are known to confer a clinical phenotype, such as the
single nucleotide polymorphisms (SNP) in the G6PD
gene that may cause severe hemolytic anemia, one may
anticipate toxicity of certain inhibitors due to on-target
effects. These on-target effects on non-tumor tissue are
unwanted during treatment but can be very informative
for evaluation of pharmacodynamic effects. Occurrence
of certain side effects (e.g., hemolytic anemia in G6PD
blockade) in early clinical trials may tell whether the in-
vestigators reached proper blockade of the target during
the treatment. Both efficacy and toxicity may therefore
provide valuable information for design of clinical trials
with these agents or their improved counterparts.
The glucose analog 2-deoxy-D-glucose (2DG) is an ex-
ample of a drug that has received renewed attention
lately (see Table 1 for an overview). A traditional dose
escalation study was performed among patients with ad-
vanced cancer as single agent as well as in combination
with docetaxel [118, 119]. On a daily dosing schedule of
45–60 mg/kg, plasma concentrations of 0.7 mM were
reached which approximates concentrations used for
preclinical RCC experiments [118, 120]. Dose-limiting
toxicities (DLTs) were fatigue, sweating, dizziness,
nausea, and prolonged QTc time. These results suggest
that 2DG may induce hypoglycemic symptoms due to
competition with systemic glucose. PET imaging in a
limited number of patients showed reduced uptake of
fluoro-deoxy glucose (FDG), indicative of potential com-
petition between FDG and 2DG in tumors. No phase 2
study has been performed with this drug in RCC.
Lonidamine is another revived chemotherapeutic agent,
which is supposed to target hexokinase in tumors. Phase 1
clinical trials have been conducted in the 1980s as single
agent as well as combined with whole body hyperthermia
[121–123]. Safety was confirmed of chronic use of oral
doses up to 360 mg/m2, yielding systemic concentrations
of 5.13 μg/mL. Side effects consisted mostly in musculo-
skeletal discomfort, anorexia, testicular pain in males, and
a reversible ototoxicity. No metabolism or target
Table 1 Overview of drugs, currently in clinical development
Drug Target Clinical stage RCC
2DG Glucose Phase 2 n.a.
Lonidamine HK Phase 2 Negative
Dichloroacetate (DCA) PDK Phase 3 n.a.
Polyphenon E LDH-A Phase 1 n.a.
FK866 GAPDH Phase 1 n.a.
AT-101 LDH-A Phase 2 n.a.
PEG-ADI Arginase 1 Phase 3 n.a.
Indoximod LAT1 Phase 2 n.a.
Acivicin Glutamine Phase 2 Negative
6-Diazo-5-oxo-L-norleucine (DON) Glutamine Phase 2 n.a.
Orlistat FASN Phase 1 n.a.
Metformin GPDH Phase 3 n.a.
NVP-BEZ235 PI3K/mTOR Phase 2 n.a.
GDC-0980 (apitolisib) PI3K/mTOR Phase 2 n.a.
SF1126 PI3K Phase 1 n.a.
BYL719 P110a Phase 2 n.a.
MLN1117 P110a Phase 2 n.a.
AZD8186 p110β Phase 1 n.a.
GSK2636771 p110β Phase 2 n.a.
SAR260301 p110β Phase 1 n.a.
Perifosine Akt Phase 2 Negative
MK-2206 Akt Phase 2 n.a.
GSK690693 Akt Phase 1 n.a.
GDC-0068 Akt Phase 2 n.a.
BEZ235 PI3K/mTOR Phase 2 n.a.
XL765 PI3K/mTOR Phase 1 n.a.
GDC0890 PI3K/mTOR Phase 2 n.a.
GSK1059615 PI3K/mTOR Phase 1 n.a.
AZD8055 mTORC1/2 Phase 1 n.a.
AZD2014 mTORC1/2 Phase 2 Negative
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inhibition analyses were performed in patients. Two phase
2 studies have been performed among patients with RCC,
showing limited clinical activity of the drug [124, 125].
One year survival rate was 37.5 % in patients treated with
lonidamine which relates unfavorable to current treatment
strategies [124]. Limited information is available on RCC
subtype and patient characteristics (e.g., Heng prognostic
score) in these trials. The results therefore have to be
interpreted with caution.
The small molecule PDK-inhibitor dichloroacetate
(DCA) is registered for patients with congenitally dys-
functional PDH. Safety and tolerability has also been
tested in patients with advanced solid tumors [126]. The
maximum tolerated dose was 6.25 mg/kg with fatigue,
nausea, and grade 3 neuropathy as dose limiting toxicity
at higher dose levels. Pharmacokinetic analysis revealed
high variability in systemic drug concentrations, possibly
related to common genetic polymorphisms in the GSTZ1/
MAAI metabolic enzyme [126, 127]. Preliminary analysis
of glioblastoma tissue from three patients treated with
DCA showed stimulation of PDH activity and accumula-
tion of α-ketoglutarate and hydrogen peroxide [128]. Fur-
ther research is warranted to determine efficacy of the
drug as potential therapeutic agent.
Based on the cancer preventive as well as therapeutic
activity of the multitargeted agent epigallocatechin gall-
ate (EGCG), phase 1 clinical trials have been conducted.
Most clinical trials used polyphenon E as a defined de-
caffeinated green tea polyphenol mixture. Doses up to
2000 mg twice daily were well tolerated with predomin-
antly mild to moderate gastrointestinal side effects such
as diarrhea and nausea [129, 130]. No dose-limiting tox-
icities or pharmacodynamic results have been reported.
The oral bioavailability was shown to be poor with large
variability and a median plasma through concentrations
of 40.4 ng/mL [130]. Although uptake was shown to be
improved by fasting prior to intake, concentrations relate
unfavorable to preclinically effective levels (5–50 times
higher) [131]. Alternative pharmacological prescriptions
are warranted for intravenous testing and maximum tol-
erable dose (MTD) determination. Current polyphenon
formulations are most likely insufficient for proper clin-
ical trials in RCC.
Metformin is a commonly used antidiabetic drug that
was found to have anticancer activity. Its favorable side-
effect profile and abundant clinical experience has urged
start of clinical trials. Beneficial effects of metformin
doses up to 2000 mg per day have been observed on the
regulation of diabetes mellitus. Retrospective cohort
studies have confirmed potential anticancer activity of
these doses in numerous patient cohorts. In a large renal
cell cancer cohort, prolonged overall survival was seen
in patients with localized disease but not in patients with
metastatic disease [132]. Prospective phase 2 trials have
been conducted, assuming maximum anticancer effects
at commonly used antidiabetic doses. No prospective
clinical trials have been done in RCC. Disease
stabilization has been observed as best response among
patients with prostate cancer, while no clinical activity
was found in patients with pancreatic cancer [133, 134].
The correlation between AMPK expression and treat-
ment response has not been subject of these analyses.
FK866 and AT-101 are two other drugs that have
reached the early stages of clinical testing. AT-101 repre-
sents an unspecific inhibitor of dehydrogenases, includ-
ing LDH-A. A phase I/II clinical trial among patients
with prostate cancer showed an MTD of 20 mg/day
[135]. Diarrhea, fatigue, nausea, and anorexia were the
most frequently observed adverse events. The GAPDH
and NAD-inhibitor FK866 was administered as a continu-
ous intravenous infusion over 96 h. Thrombocytopenia
was the dose limiting toxicity, yielding an MTD of
0.126 mg/m2/hour [136]. In addition, lymphopenia,
anemia, and liver test abnormalities were observed. No
metabolic analysis was performed during treatment with
these inhibitors.
Pegylated arginine deiminase (PEG-ADI) and the IDO-
inhibitor indoximod are drugs that underwent phase 1/2
clinical testing. Increasing doses of the arginine deplet-
ing enzyme PEG-ADI were given to 31 patients with
melanoma with ASS1 negative tumors [137]. Pharmaco-
dynamic analysis revealed neutralization of systemic ar-
ginine in 30/31 patients at day 8 after the start of
treatment. No RECIST based responses were measured
[137] with eight patients having stable disease as best re-
sponse. No dose-limiting toxicities were seen during
treatment. Indoximod has also been subject of a phase 1
clinical trial in 48 patients with advanced solid tumors
[138]. The maximum tolerated dose was 2000 mg twice
daily. Hypophisitis, tumor antigen autoantibodies, and
elevated CRP levels were observed at several dose levels
and suggest a reduction of immunosuppressive effects in
tumors. Phase 2 clinical trials are underway.
Acivicin and 6-diazo-5-oxo-L-norleucine (DON) are
glutamine antagonists that have been tested in patients
with cancer. Acivicin and DON can both be isolated
from Streptomyces sviceus bacterial cultures and are
structurally related to glutamine. Dose escalation studies
among patients with advanced cancer revealed MTDs of
600 mg/m2 for DON [139]. Multiple dosing regimens
have been used for treatment with acivicin. Doses ran-
ging from 15 mg/m2/day on five consecutive days to
160 mg/m2/day as single 24-h infusions were recom-
mend by these studies [140, 141]. Acute dose-dependent
nausea, vomiting, and diarrhea were DLTs after treat-
ment with DON. Acivicin induced myelosuppression
and neuropsychiatric symptoms (paresthesia, weakness,
hallucinations, psychosis, confusion) as dose-limiting
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toxicities. These last symptoms were attributed to the
potential neurotransmitter like properties of acivicin.
Concomitant intravenous administration of amino acid
mixtures was shown to reduce CNS toxicity and there-
fore allowed further dose escalation [142]. Pharmacody-
namic analysis of amidotransferase acitivity in ascites
derived tumor cells showed suppression by acivicin
[140]. A randomized phase 2 trial has been performed
with acivicin among patients with advanced RCC [143].
One partial response was observed after treatment with
20 mg/m2 for 72 h among 27 patients.
The FASN inhibitor orlistat is a drug that is approved
for weight management in over 120 countries. A ran-
domized double blind study among 539 obese individ-
uals showed safety and good tolerability of the drug at a
dose of 120 mg once daily [144]. However, negligible
systemic absorption renders the oral drug unsuitable for
treatment of patients with cancer [145]. Further research
is needed to determine potential use of alternative
pharmacological formulations of this drug.
Clinical experience with PI3K-AKT-mTOR inhibitors
As downstream mediator of receptor tyrosine kinase
(RTK) signaling as well as mutated hotspot itself, PI3K
represents an attractive therapeutic target. A variety of
inhibitors, including the previously described drugs
NVP-BEZ235, GDC-0980, and SF1126, have entered
clinical trials. PI3K targeting drugs can be divided in
pan-PI3K- and isoform-specific PI3K inhibitors. Multiple
pan-PI3K inhibitors underwent phase 1 and 2 clinical
testing and showed limited toxicity and at best modest
clinical activity [146]. Dose-limiting effects included
hyperglycemia, maculopapular skin rash, and gastrointes-
tinal intolerance (nausea, anorexia, diarrhea) [147–150].
AKT phosphorylation in blood, skin, or tumor tissue has
been used as pharmacodynamic biomarker and showed a
decrease, ranging from 40 to 90 %. FDG-PET imaging also
showed marked metabolic responses in a small subset of
patients [147]. Whether these effects are sufficient to in-
duce durable treatment responses in patients with RCC is
questionable. It has been conjectured that the essential
role of PI3K in healthy tissues may limit dosing and re-
strict impact on tumors. Recent success with the δ-
isoform-specific PI3K-inhibitor idelalisib in hematological
malignancies [151] urged investigation of such specific in-
hibitors in solid tumors as strategy to circumvent these
potential limitations of pan-PI3K inhibition. RCC tu-
mors are known to harbor frequent PTEN and PIK3CA
mutations. Previous research indicated that PTEN loss
should be targeted by p110β-inhibitors [152], while
PIK3CA mutations ask for p110α selective inhibitors
[153]. The first clinical results of p110α selective
(BYL719, MLN1117) and p110β-selective (AZD8186,
GSK2636771, SAR260301) inhibitors are now emerging.
Phase 2 clinical trials in patients with RCC will be re-
quired to further elucidate the role of these inhibitors
in this disease.
AKT acts as critical downstream mediator of PI3K and
has been postulated as “the Warburg kinase.” Perifosine
and MK-2206 are examples of AKT inhibitors that were
subject of phase 1 clinical trials [154, 155]. GSK690693
and GDC-0068 are ATP-competitive AKT inhibitors tar-
geting all three isoforms that are currently under investi-
gation. Dose-limiting toxicities were skin rash, nausea,
diarrhea, pruritus, and hyperglycemia. AKT phosphoryl-
ation declined in tumor biopsies after treatment with
MK-2206 [154]. Two phase 2 trials were conducted with
perifosine among patients with RCC, showing limited
clinical activity of the drug. No metabolic analysis has
been performed in studies that employed AKT inhibi-
tors. Preclinical studies suggested AKT-independent sig-
naling pathways in PIK3CA mutated cell lines, possibly
explaining limited clinical activity of perifosine [156].
Preclinical experiments suggest improved antitumor
activity of dual targeting of PI3K/mTOR or mTORC1/
mTORC2. Mutation of PIK3CA predisposes to a favor-
able response to rapalogs [157]. An elevated systemic
LDH level before start of treatment was found to be as-
sociated to overall survival of patients with RCC treated
with temsirolimus [158]. In both publications, the au-
thors speculated that the biomarkers are indicative of
pathway activation, which may explain their association
with response to mTOR inhibitors. The drugs BEZ235,
XL765, GDC-0890, and GSK1059615 are examples of
dual PI3K/mTOR inhibitors. Phase 1 results from clin-
ical tests with BEZ235 and XL765 have been published
and showed similar toxicity profiles as with pan-PI3K in-
hibitors [159, 160]. AZD8055 and AZD2014 are exam-
ples of dual mTORC1/2 inhibitors that went through
phase 1 testing [161, 162]. AZD2014 was shown to in-
hibit p-S6 in tumor biopsies. A randomized phase 2 trial
has been conducted with AZD2014, comparing its effi-
cacy with everolimus [163]. The clinical trial was
stopped early due to inferior activity of AZD2014 in this
patient cohort, despite adequate systemic drug concen-
trations. No results of pharmacodynamic analysis of
tumor tissue were described.
The impact of VEGF and mTOR inhibitors on tumor
metabolism
Molecular profiling studies identified metabolic alter-
ations as poor prognostic parameters. It has been sug-
gested that upregulation of aerobic glycolysis and
lipogenesis are part of the natural disease course and
may aid in tumor progression. Most of these studies
were performed in the era of targeted therapy, with
VEGF-targeted drugs and mTOR inhibitors as estab-
lished treatment modalities. Treatment poses selective
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pressure, allowing expansion of certain clones with ad-
vantageous molecular features. We here briefly review
drug resistance against VEGF- and mTOR-targeted in-
hibitors and its role in directing tumor metabolism.
VEGF-targeted drugs are known to interfere with
angiogenesis, significantly compromising oxygen and
nutrient supply. Aerobic glycolysis seems an efficient
way to cope with certain aspects of these types of meta-
bolic stress, since it requires little oxygen. A compre-
hensive analysis of the impact of VEGF-targeted agents
on tumor metabolism has been performed in lung and
breast cancer xenografts. Upregulation of glycolysis and
lipogenesis was found during treatment with the VEGF
inhibitors sunitinib or sorafenib in this study [164].
Similarly, the VEGF-neutralizing antibody bevacizumab
was shown to promote lactate production and activa-
tion of the PI3K-pathway in glioblastoma xenografts
[165, 166]. Analysis of RCC tumor tissue after treat-
ment with erlotinib and bevacizumab revealed an asso-
ciation between poor treatment response and low
AMPK expression or activation of the PI3K-pathway.
Sequential FDG-PET imaging during sunitinib treat-
ment in patients with RCC showed high glucose uptake
associated with poor treatment response [167]. These
observations indicate that VEGF-targeted drugs may
aid in selection of tumor cells with altered metabolism
and/or activation of PI3K. Treatment with orlistat,
DCA, and PI3K inhibitors restored the sensitivity to
VEGF-targeted drugs in preclinical models, demon-
strating potential of combination treatment strategies
[164, 166, 168].
The rapalogs everolimus and temsirolimus interfere
with mTOR signaling in tumor cells. Multiple resist-
ance mechanisms have been identified in the last dec-
ade. These mechanisms include activation of MAPK-
pathway through a PI3K-mediated feedback loop and
increased survivin expression [169, 170]. TSC1/2 mu-
tations were shown to predispose to a favorable treat-
ment response [171]. Furthermore, mTOR acts as an
energy sensor in cells and its inhibition leads to the
activation of salvage pathways for the generation of
energy, such as autophagy or utilization of extracellu-
lar amino acids [172, 173]. Functional interference
with these salvage pathways can result in synthetic le-
thal effects in cancer cells. For example, severe cyto-
toxic effects of combined autophagy- and mTOR
inhibition have been detected in mantle cell lymph-
oma cells [174]. Similarly, targeting compensatory up-
regulation of glutamine metabolism in glioblastoma
xenografts induced severe cytotoxic effects [175]. The
implications of “the metabolic shift” in RCC for the
sensitivity to mTOR inhibitors, or the impact of
mTOR inhibitors on metabolism are currently un-
known and warrant further investigation.
Conclusions
Molecular profiling studies have uncovered a pro-
nounced metabolic shift in tumors of patients with
ccRCC. Aerobic glycolysis, upregulation of lipogenesis
and activation of the PI3K pathway are hallmarks of the
disease. HIF1/2, MYC, and mTOR are deemed essential
players in this feature. Preclinical research has revealed
several promising therapeutic targets in these pathways,
among them G6PD, PFK-FB3, and LDH-A. Several
therapeutic agents showed promising pharmacodynamic
effects and have been tested with success in preclinical
models of RCC and are therefore awaiting clinical evalu-
ation. Particularly, dual inhibitors of PGAM1 and 6-
PGDH (e.g., PGMI-004A) and inhibitors of the relatively
cancer-specific target PFK-FB3 such as PFK15 warrant
further investigation. Disappointing results have been
obtained in clinical trials with a number of drugs (e.g.,
orlistat, polyphenon E) due to a suboptimal pharmaco-
logical formulation. In other clinical studies a thorough
pharmacodynamic analysis during treatment was lack-
ing, limiting the possibility to draw conclusions on the
viability of the drug targets. Novel PI3K-AKT-mTOR in-
hibitors have arrived in the clinic. Thus far, the results
have however been disappointing, possibly due to a lack
of tumor- or drug target-specificity. Future trials will rely
on careful design, proper patient selection, and thorough
analysis of the pharmacodynamic effects of drugs in order
to shift paradigms and move towards new treatment regi-
mens. To this end, combined molecular characterization
before start and after treatment may be of critical import-
ance for adequate treatment selection. Given the fact that
metabolic remodeling in RCC carries a poor prognosis
and aids in disease progression, therapeutic agents that
interfere with this process may shape the future of pa-
tients with advanced RCC.
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